Results 261 to 270 of about 125,579 (360)
The Platelet-to-Lymphocyte Ratio (PLR) as a Non-Invasive Biomarker for Cervical Malignancy in Conization Patients. [PDF]
Kalas N +12 more
europepmc +1 more source
Abstract Purpose The present study aimed to compare the efficacy and safety of a combined injection of stromal vascular fraction (SVF) and platelet rich plasma (PRP) versus a high molecular weight (HMW) hyaluronic acid (HA) injection in patients with knee osteoarthritis (KOA).
Trifon Totlis +6 more
wiley +1 more source
Carotid intima media thickness, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio in multiple sclerosis. [PDF]
Eissazade N +4 more
europepmc +1 more source
Inflammatory Markers Stratify Surgical Outcomes in Pediatric Airway Reconstruction
ABSTRACT Objectives Red blood cell distribution width (RDW) predicts surgical success in adult patients undergoing open airway reconstruction for laryngotracheal stenosis, but similar biomarkers in pediatrics remain unidentified. This study identifies predictors of outcomes in pediatric patients undergoing triple endoscopy or surgical airway ...
Nomongo Dorjsuren +5 more
wiley +1 more source
Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T‐Cell Biomarkers
ABSTRACT Objective Head and neck squamous cell carcinoma (HNSCC) lacks reliable prognostic circulating biomarkers, and the role of the immune system in its progression remains incompletely understood. This study aimed to evaluate the prognostic value of systemic inflammatory and immune biomarkers in surgically treated patients with primary oral cavity (
Riccardo Gili +10 more
wiley +1 more source
A Cross-Sectional Study of Platelet-to-Lymphocyte Ratio in Relation to Pigment Cell Nevi and Atypical Mole Syndrome. [PDF]
Nevakivi R +3 more
europepmc +1 more source
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source

